Local delivery of 131I-MIBG to treat peritoneal neuroblastoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 9, 2003, Pages 1246-1250

  Kinuya, Seigo ^a   Li, Xiao Feng ^a   Yokoyama, Kunihiko ^a   Mori, Hirofumi ^b   Shiba, Kazuhiro ^b   Watanabe, Naoto ^c   Shuke, Noriyuki ^d   Bunko, Hisashi ^e   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

131I MIBG; Internal radio therapy; Intraperitoneal administration; Neuroblastoma; Peritoneal spread

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; MOUSE; NEUROBLASTOMA; NONHUMAN; PERITONEUM; RADIATION DOSE; RADIOACTIVITY; SURVIVAL TIME; TREATMENT OUTCOME;

3-IODOBENZYLGUANIDINE; ANIMALS; BODY BURDEN; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROBLASTOMA; ORGAN SPECIFICITY; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 12444347388     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1214-1     Document Type: Article

References (25)

1. Hoefnagel CA. Targeted radiotherapy of neuroblastoma. In: Abrams PG, Fritzberg AR, eds. Radioimmunotherapy of cancer. New York: Marcel Dekker, Inc.; 2000: 339-359
2. Oliphant M, Berne AS. Mechanism of direct spread of abdominal neuroblastoma: CT demonstration and clinical implications. Gastrointest Radiol 1987; 12: 59-66
3. Fernbach SK. Ascites produced by peritoneal seeding of neuroblastoma. Pediatr Radiol 1993; 23: 569
4. Chung CJ, Bui V, Fordham LA, Hill J, Bulas D. Malignant intraperitoneal neoplasms of childhood. Pediatr Radiol 1998; 28: 317-321
5. Kaste SC, Marina N, Fryrear R, et al. Peritoneal metastases in children with cancer. Cancer 1998; 83: 385-390
6. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localisation of intraperitoneal tumours following intraperitoneal or intravenous antibody administration. Cancer Res 1987; 47: 6528-6531
7. Buijs WC, Tibben JG, Boerman OC, et al. Dosimetric analysis of chimeric monoclonal antibody cMOv 18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration. Eur J Nucl Med 1998; 25: 1552-1561
8. Larson SM, Carrasquillo JA, Colcher DC, et al. Estimates of radiation absorbed dose for intraperitoneally administered iodine-2 131 radiolabelled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 1991; 32: 1661-1667
9. Quadri SM, Malik AB, Chu HB, Freedman RS, Vriesendorp 2 HM. Intraperitoneal indium-111- and yttrium-90-labelled human IgM (AC6C3-2B 12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med 1996; 37: 1545-1551
10. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 2001; 16: 305-315
11. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996; 37: 1491-1496
12. Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985; 3: 1-6
13. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001; 61: 1057-1065
14. Kinuya S, Yokoyama K, Kawashima A, et al. Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of RIT in human colon cancer xenografts. J Nucl Med 2000; 41: 1244-1249
15. Kinuya S, Kawashima A, Yokoyama K, et al. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Eur J Nucl Med 2001; 28: 1306-1312
16. Cheung N-KV, Landmeier B, Neely J, et al. Complete tumour ablation with iodine 131-radiolabelled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 1986; 77: 739-745
17. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991; 35: 244-247
18. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991; 18: 308-316
19. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994; 21: 545-559
20. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236
21. Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989; 49: 2941-2944
22. Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990; 39: 1959-1964
23. Iavarone A, Lasorella A, Servidei T, Riccardi R, Mastrangelo R. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993; 53: 304-309
24. Mairs RJ, Cunningham SH, Russell J, et al. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med 1995; 36: 1088-1095
25. Rutgers M, Buitenhuis CK, Hoefnagel CA, Voute PA, Smets LA. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy. Int J Cancer 2000; 87: 412-422